Rapport Therapeutics, Inc.
live · Yahoo FinanceLimited buying: $22.0M bought (counted up to $5.0M); 7 distinct insiders. Holding it back: largest buyer: Ignelzi Troy A. (CFO), 92% of the dollars.
AI summary RAPP CFO and directors buy $1.66M on open market after Phase 2 readout, followed by $20.36M fund purchase at offering price
Score, not a recommendation.
Price and insider purchases
Live chart from Yahoo Finance, loaded through this server; our daily closes when it is unavailable.
Loading price history…
How the score adds up
How each input is counted →| Input | Strength | Points |
|---|---|---|
| $22.0M bought (counted up to $5.0M)The dollars the insiders bought, a purchase reported jointly counted once, counted from $131. Each tenfold adds 12.4 points, up to $5.0M; more adds nothing. The bar is empty at $10.0K and full at $5.0M. | 100% | +57 |
| 7 distinct insidersHow many different insiders bought. Each extra insider adds less than the one before (the points follow the log of the count: 4.3 per doubling). The bar is full at 10 insiders. | 85% | +12 |
| No CEO among the buyersWhether the chief executive is among the buyers: 10.6 points when yes. | 0% | +0 |
| Stock 44% below its 1-year high (counted up to 30%)How far the stock had fallen from its highest close of the past year, at the close before the buying. Every 10% of fall adds 1.9 points. A fall beyond 30% adds nothing more. The bar is full at a 30% fall. | 100% | +6 |
| 7 days from first to last purchaseDays between the first and the last purchase. Each day takes off 0.11 points: buying close together keeps more. The bar is empty at 60 days. | 88% | -1 |
| Routine or plan purchases: 0% of the dollars | 100% | +0 |
| Largest buyer: Ignelzi Troy A. (CFO), 92% of the dollars | 9% | -12 |
| Match scoreA score from 0 to 100 worked out from the dollars bought, the number of insiders, whether a CEO bought, how far the stock had fallen, how spread out the purchases were and how much came from one buyer. Its weights were calibrated on past clusters. It is the default ranking of the lists and it decides which clusters get the AI review. It describes the buying; it is not a forecast. | 62 | |
| AI adjustmentPoints added or taken off by a language model that reads the SEC filings and recent news about the cluster and classifies the buying (for example open market, plan or offering). It can be wrong, it is shown as its own line, and it is never used in past results. | -5 | |
| Insider ScoreThe number from 0 to 100 shown on each cluster and used to rank the lists. By default it is the match score, plus the points of the AI review when there is one. It describes the buying; it is not a forecast or a recommendation. | 57 | |
Why are they buying?
AI · mixed · catalyst credible · partialSix insiders (the CFO and five directors) likely bought $1.66M of RAPP stock on October 21-23 because shares had fallen 25.9% over 21 days and sat 44.1% below their 1-year high around the October 20 Phase 2 bipolar mania readout. On October 28, director James Healy's affiliated funds purchased $20.36M at exactly $21.00 per share, matching the date and $21.00 pricing of the company's October 28-30 equity offering and concurrent private placement, though the Form 4 does not explicitly state offering participation.
Three directors initiated new positions and the other four buyers increased existing stakes by 40% to 86%, with none of the seven having sold shares in the prior three years and $0 in non-plan insider sales over the past 90 days. Following the late-October equity and convertible note financing, Rapport Therapeutics reported $815.4M in cash and cash equivalents as of November 3, 2026, providing runway through the end of 2029.
Filing references and sources
- Form 4 - Ignelzi Troy A. (opens in a new tab)
- Form 4 - Maraganore John (opens in a new tab)
- Form 4 - Paul Steven M (opens in a new tab)
- Form 4 - Young Wendy B. (opens in a new tab)
- Form 4 - Silva Paul M (opens in a new tab)
- Form 4 - Sanchez Ramiro (opens in a new tab)
- Form 4 - Healy James (opens in a new tab)
- Rapport Therapeutics Announces Positive Topline Results from its Phase 2 Trial of RAP-219 for the Treatment of Bipolar Mania (8-K Ex-99.1) (opens in a new tab)
- Rapport Therapeutics Reports Third Quarter 2026 Financials and Provides Business Update (8-K Ex-99.1) (opens in a new tab)
- Rapport Therapeutics (RAPP) Shares Decline -34% in 30 Days on Bipolar Mania Readout (opens in a new tab)
- Rapport Therapeutics Strengthens Capital Base with New Financing - The Globe and Mail (opens in a new tab)
| Date | InsiderAn officer or director of a company, or an owner of more than 10% of its shares. The law requires them to report their trades in the company's stock to the SEC. | Role | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-10-28 | HEALY JAMES history of HEALY JAMES's purchases | Director | 969,480 | $21.00 avg | $20.4M | |
| 2026-10-28 | HEALY JAMES | 6,395 | $21.00 | $134.3K | SEC filing for HEALY JAMES (opens in a new tab) | |
| 2026-10-28 | HEALY JAMES | 952,380 | $21.00 | $20.0M | SEC filing for HEALY JAMES (opens in a new tab) | |
| 2026-10-28 | HEALY JAMES | 3,772 | $21.00 | $79.2K | SEC filing for HEALY JAMES (opens in a new tab) | |
| 2026-10-28 | HEALY JAMES | 6,933 | $21.00 | $145.6K | SEC filing for HEALY JAMES (opens in a new tab) | |
| 2026-10-22 | PAUL STEVEN M history of PAUL STEVEN M's purchases | Director | 35,714 | $27.28 | $974.3K | SEC filing for PAUL STEVEN M (opens in a new tab) |
| 2026-10-22 | MARAGANORE JOHN history of MARAGANORE JOHN's purchases | Director | 9,411 | $26.45 avg | $248.9K | |
| 2026-10-22 | MARAGANORE JOHN | 1,172 | $26.92 | $31.5K | SEC filing for MARAGANORE JOHN (opens in a new tab) | |
| 2026-10-22 | MARAGANORE JOHN | 8,239 | $26.38 | $217.3K | SEC filing for MARAGANORE JOHN (opens in a new tab) | |
| 2026-10-21 | Ignelzi Troy A. history of Ignelzi Troy A.'s purchases | CFO | 5,500 | $26.10 | $143.6K | SEC filing for Ignelzi Troy A. (opens in a new tab) |
| 2026-10-22 | Young Wendy B. history of Young Wendy B.'s purchases | Director | 3,789 | $26.39 | $100.0K | SEC filing for Young Wendy B. (opens in a new tab) |
| 2026-10-22 | Silva Paul M history of Silva Paul M's purchases | Director | 3,680 | $27.07 | $99.6K | SEC filing for Silva Paul M (opens in a new tab) |
| 2026-10-23 | Sanchez Ramiro history of Sanchez Ramiro's purchases | Director | 3,600 | $27.35 | $98.5K | SEC filing for Sanchez Ramiro (opens in a new tab) |
| Total | $22.0M | |||||
Other buying runs at RAPP
A buying runPurchases at one company with no pause longer than the cluster rule allows. A long pause ends the run, so one company can have several. ends after a pause in the buying, so one company can have several. Returns are the stock's return minus its benchmarkThe index a stock's return is compared with: a small-cap index for small companies, a large-cap index otherwise. (IWM for small companies, SPY otherwise), from the first open after the buying run became a cluster. Past results, not a forecast.
After this buying run became a cluster, vs benchmark: 21 days –63 days –126 days –
| Window | Insiders | Total | Score | 21 days vs benchmark | 63 days vs benchmark | 126 days vs benchmark | Status |
|---|---|---|---|---|---|---|---|
| 2025-09-11 → 2025-09-12 | 3 | $1.6M | 55 | -4.8% (+0.2% raw) | +9.3% (+15.0% raw) | -0.8% (+2.9% raw) | closed |